Details for Patent: 9,738,625
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 9,738,625 protect, and when does it expire?
Patent 9,738,625 protects IDHIFA and is included in one NDA.
This patent has forty patent family members in twenty-three countries.
Summary for Patent: 9,738,625
| Title: | Therapeutically active compounds and their methods of use |
| Abstract: | Provided are isocitrate dehydrogenase 2 (IDH2) inhibitor compounds useful for treating cancer and methods of treating cancer, comprising administering to a subject in need thereof a compound described herein. Also provided are polymorphic forms of the IDH2 inhibitor compounds characterized by X Ray powder diffraction patterns, having improved physicochemical properties that influence in vivo dissolution rate for formulation purposes. |
| Inventor(s): | Agresta; Samuel V. (Lexington, MA), Gu; Chong-Hui (Waban, MA), Schenkein; David (Boston, MA), Yang; Hua (Acton, MA), Guo; Liting (Suzhou, CN), Tang; Zhen (Suzhou, CN), Wang; Jianming (Suzhou, CN), Zhang; Yanfeng (Suzhou, CN), Zhou; Yan (Suzhou, CN) |
| Assignee: | Agios Pharmaceuticals, Inc. (Cambridge, MA) |
| Application Number: | 14/909,451 |
|
Patent Claim Types: see list of patent claims | Compound; |
Drugs Protected by US Patent 9,738,625
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bristol Myers Squibb | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-001 | Aug 1, 2017 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
| Bristol Myers Squibb | IDHIFA | enasidenib mesylate | TABLET;ORAL | 209606-002 | Aug 1, 2017 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 9,738,625
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| PCT/CN2013/081170 | Aug 9, 2013 | |
| PCT Information | |||
| PCT Filed | August 01, 2014 | PCT Application Number: | PCT/US2014/049469 |
| PCT Publication Date: | February 05, 2015 | PCT Publication Number: | WO2015/017821 |
International Family Members for US Patent 9,738,625
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Argentina | 097237 | See Plans and Pricing | |||
| Australia | 2014295938 | See Plans and Pricing | |||
| Australia | 2018247242 | See Plans and Pricing | |||
| Brazil | 112016002287 | See Plans and Pricing | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
